Acute Leukemias II: Prognostic Factors and Treatment Strategies

ISBN-13: 9783540509844 / Angielski / Miękka / 1990 / 776 str.

Thomas Ba1/4chner; Gunther Schellong; Wolfgang Hiddemann

Opis

Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero unsatisfactory cure rates even in special sub geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa effective supportive care show some increase tients other cases prove to be highly resis in the initial response rates and certain im tant. The curability is superior in acute provements in the long-term results, no ben lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML."

Spis treści

Leukemia Cell Biology and Basic Science.- Myelodysplastic Syndromes: Preleukemic or Early Leukemic Conditions?.- Mechanisms of Autocrine and Paracrine Growth Control in Acute Myelogenous Leukemia.- Clonal Analysis of Human Leukemias by Molecular Genetic Approaches.- Clinical Relevance of Cytogenetics in Acute Leukemia.- Minimal Residual Disease in Acute Leukemia: Lessons Learned from Animal Models.- Toward Improvement of Therapeutic Strategies in Leukemia by Amplification of the Immune Response Against Leukemia.- Double Marker Analysis for Terminal Deoxynucleotidyl Transferase and Myeloid Antigens in Acute Nonlymphocytic Leukemia Patients and Healthy Subjects.- Antigen Receptor Rearrangement and Expression in Acute Leukemias.- Immunoglobulin and T-Cell Receptor Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma.- Heterogeneity in Protein Patterns of CGL Blast Crisis Cells: Discrimination Between Lymphatic and Myeloic Lineages.- Correlation Between the Expression of Myelomonocytic Surface Antigens and Ultrastructural Demonstration of Early Myeloperoxidase Expression in Null-AL (L) Cells.- Interleukin-1 Production in Childhood Acute Lymphoblastic Leukemia During Chemo- and Radiotherapy According to BFM (Berlin-Frankfurt-Münster) Protocol.- Determination of Soluble Interleukin-2 Receptors After Bone Marrow Transplantation.- Synergism of H2-Histamine Receptor Antagonists with Alpha-Interferon to Inhibit the Growth of Leukemic and Normal Hematopoietic Progenitors.- Dependence of Serum Erythropoietin Level on Erythropoiesis in Leukemia.- Transferrin Derivatives with Growth Factor Activities in Acute Myeloblastic Leukemia: An Autocrine/Paracrine Pathway.- In Vitro Effects of G-CSF, GM-CSF, and IL-3 on Leukemic Cells of Children with Acute Nonlymphoblastic Leukemia.- In Vitro Growth Kinetics of Myeloid Progenitors Cells of Myelodysplastic Patients in Response to Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3.- Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia: Augmentation of LAK-Cell Cytotoxicity by Combinations of Lymphokines or Cytokines.- Biochemical Evidence for Synergistic Combination Treatment with Methotrexate and 6-Mercaptopurine in Acute Lymphoblastic Leukemia.- Pharmacokinetics of Folinic Acid in Children with Acute Lymphoblastic Leukemia.- Cellular Pharmacokinetics of Daunomycin in Human Leukemic Blasts In Vitro and In Vivo.- Synergistic Cytotoxicity of Cystosine Arabinoside and Mitoxantrone for K562 and CFU-GM.- Mafosfamide Induces Less Sister Chromatid Exchange in Ph-Positive Cells Than in Normal Bone Marrow.- Blood Concentration of Ascorbyl-Free Radical in Children with Acute Lymphoblastic Leukemia: Preliminary Report.- Association of GP40/CD7+ Acute Myeloblastic Leukemia and Chromosome 5 Aberrations.- Acute Monocytic Leukemia with Translocation t(1;11) (p31;q23): Simultaneous Staining of Chromosomes and Cell Surface Antigens.- Prognostic Significance of Chromosome Analysis in De Novo Acute Myeloid Leukemia.- Chromosomal Aberrations in Childhood Acute Nonlymphoblastic Leukemia.- Cytogenetic Study of 130 Childhood Acute Nonlymphocytic Leukemias.- Changes in Clonal Growth, Immunophenotype, and Morphology During a Follow-up Study of an Acute Lymphoblastic Leukemia.- Prognostic Significance of the Karyotype in Patients with Primary Myelodysplastic Syndrome.- Update of the Cytogenetic Study of Childhood Non-High-Risk Acute Lymphocytic Leukemia at Diagnosis in Protocol VI of the Dutch Childhood Leukemia Study Group.- Prognosis and DNA Aneuploidy in Children with Acute Lymphoblastic Leukemia.- Acute Myelogenous Leukemia in Children.- Improved Treatment Results in the Myelocytic Subtypes FAB M1-M4 but not in FAB M5 After Intensification of Induction Therapy: Results of the German Childhood AML Studies BFM-78 and BFM-83.- Intensive Sequential Chemotherapy for Children with Acute Myelogenous Leukemia.- Therapy of Childhood Acute Nonlymphocytic Leukemia: The Pediatric Oncology Group Experience (1977–1988).- Preliminary Results of Intensive Therapy of Children and Adolescents with Acute Nonlymphocytic Leukemia — A Childrens Cancer Study Group Report.- High-Dose Ara-C as a Single-Agent Consolidation Therapy in Childhood Acute Myelogenous Leukemia.- Therapy of Childhood Acute Myelogenous Leukemia: An Update of the AIEOP/LAM 8204 Study.- Prognostic Significance of Eosinophilia in Acute Myelomonocytic Leukemia in Relation to Induction Treatment.- Treatment of Childhood Acute Nonlymphocytic Leukemia: Cooperative Austrian-Hungarian Study AML-IGCI-84.- Acute Myelogenous Leukemia in Adults.- Morphology, Immunology, Cytochemistry, and Cytogenetics and the Classification of Subtypes in Acute Myeloid Leukemia.- Remission Induction and Postremission Therapy in Acute Myelogenous Leukemia: British MRC Study.- Therapy of Acute Myelogenous Leukemia in Adults.- Consolidation Therapy with High-Dose Cytosine Arabinoside: Experiences of a Prospective Study in Acute Myeloid Leukemia.- Adult AML: The Role of Chemotherapy Intensity and Duration. Two Studies of the AML Cooperative Group.- Comparison of Postremission Therapies in Adult Acute Myeloid Leukemia: Preliminary Analysis of an ECOG Study.- EORTC Leukemia Group Trials on Acute Myeloid Leukemias: An Overview.- A Randomized Comparison of Intensive Maintenance Treatment for Adult Acute Myelogenous Leukemia Using Either Cyclic Alternating Drugs or Repeated Courses of the Induction-Type Chemotherapy: AML-6 Trial of the EORTC Leukemia Cooperative Group.- Predictive Models for Achievement of Complete Remission and Duration of First Remission in Adult Acute Myeloid Leukemia.- Sequential Decision Strategy of the AML Cooperative Group Studies.- Pretherapeutic Drug Testing in Acute Leukemias for Prediction of Individual Prognosis.- Double Intensive Consolidation Chemotherapy (ICC) for Acute Myeloid Leukemia.- Intensive Induction Therapy with Behenoyl Cytosine Arabinoside, Danorubicin, and 6-Mercaptopurine Followed by Intensive Consolidation with Mitoxantrone, Etoposide, Vincristine, and Intermediate-Dose Continuous Cytarabine (M-85 Protocol) for Adult Acute Myelogenous Leukemia.- Acute Nonlymphocytic Leukemia in Adults: Results Obtained with TAD Remission Induction Therapy.- Combination Therapy with Mitoxantrone and Etoposide in Adult Acute Myelogenous Leukemia.- Combination of Mitoxantrone and Etoposide in Patients Aged over 60 Years with Untreated Acute Myelogenous Leukemia.- Mitoxantrone in the Treatment of Acute Leukemia.- Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia.- Mitoxantrone and Etoposide in Patients with Relapsed and Refractory Acute Nonlymphocytic Leukemia.- Continuous Infusion of Mitoxantrone Combined with High-Dose Cytarabine in Refractory/Relapsed Acute Myeloblasts Leukemia and Blast Crisis of Chronic Myelogenous Leukemia.- Intermediate Dose Ara-C/m-AMSA for Remission Induction and High-Dose Ara-C/m-AMSA for Intensive Consolidation in Relapsed and Refractory Adult Acute Myelogenous Leukemia.- Treatment of Recurrent Acute Myelogenous Leukemia at a Single Centre Over a 10-Year Period.- Oral Idarubicin in Elderly Acute Leukemia and Refractory Anemia with Excess of Blasts.- Acute Promyelocytic Leukemia: Clinical Findings and Therapeutic Results in 30 Patients.- Magnetic Resonance Imaging Follow-up in Patients with Acute Leukemia During Induction Chemotherapy.- Thrombin Generation in Acute Myeloblastic Leukemia.- Acute Megakaryoblastic Leukemia: A Case Report.- Acute Megakaryoblastic Leukemia (FAB-M7) in an Infant Presenting with Orbital Chloroma and Meningeal Involvement.- Risk of Leukemic Transformation in Two Types of Acquired Idiopathic Sideroblastic Anemia.- Treatment of Advanced Myelodysplastic Syndromes: Trend Toward More Aggressive Chemotherapy?.- Chronic Myelomonocytic Leukemia: Clinical Data, Morphological Features, and Outcome in 56 Patients.- Chemotherapy of Acute Myeloid Leukemia of 35- to 60-Year-Old Patients.- Acute Lymphoblastic Leukemia in Adults.- Importance of Long-Term Follow-up in Evaluating Treatment Regimens for Adults with Acute Lymphoblastic Leukemia.- Comparison of Chemotherapy and Autologous and Allogeneic Transplantation as Postinduction Regimen in Adult Acute Lymphoblastic Leukemia: A Preliminary Multicentric Study.- Intensive Chemotherapy for Acute Lymphoblastic Leukemia in Adults.- Clinical Importance of T-ALL Subclassification According to Thymic or Pretyhmic Maturation Stage.- Treatment of Adult Acute Lymphoblastic Leukemia.- Treatment of Relapsed Acute Lymphocytic Leukemia in Adults.- Acute Lymphoblastic Leukemia in Children.- Results and Significance of Six Randomized Trials in Four Consecutive ALL-BFM Studies.- Cytogenetics of Childhood Acute Lymphoblastic Leukemia in German Multicenter Trials.- More is Better! Update of Dana-Farber Cancer Institute/Children’s Hospital Childhood Acute Lymphoblastic Leukemia Trials.- Treatment of Acute Lymphoblastic Leukemia: Protocol Fralle 83–85.- Dutch Childhood Leukemia Study Group: Early Results of Study ALL VI (1984–1988).- Results of Acute Lymphoblastic Leukemia Therapy in Childhood: GDR-Experiences 1981–1987.- Impact of Early Intensive Reinduction Therapy on Event-Free Survival in Children with Low-Risk Acute Lymphoblastic Leukemia.- Improved Prognosis for Childhood Acute Lymphocytic Leukemia with Very High White Blood Cell Count (>100/nl) with Rotation of Non-Cross-Resistant Drug Combinations.- Prognosis of Initial CNS Involvement in Acute Lymphocytic Leukemia in Childhood.- Central Nervous System Relapse Prevention in 1165 Standard-Risk Children with Acute Lymphoblastic Leukemia in Five BFM Trials.- Effective Prevention of Central Nervous System Leukemia with Intrathecal Methotrexate and Intrathecal Methotrexate, Cytosine Arabinoside, and Hydrocortisone in Childhood Acute Lymphocytic Leukemia.- Risk of CNS Relapse After Systemic Relapse of Childhood Acute Lymphoblastic Leukemia.- Incidence and Clinical Implications of Acute Hybrid Leukemia in Childhood.- Supportive Care in Acute Leukemias.- Prevention of Infection in Acute Leukemia.- The Febrile Neutropenic Patient: Newer Options for Empirical Therapy.- Supportive Care of the Marrow Transplant Recipient: The Seattle Experience.- Management of Fungal Infection in Neutropenic Patients with Fluconazole.- Prevention of Bacteremias Caused by Hemolytic Streptococci by Roxithromycin in Patients Treated with Intensive Cytotoxic Treatment.- Hepatosplenic Candidosis in Acute Leukemias.- Effect of Antifungal Therapy on Hematological Recovery After Intensive Antileukemic Chemotherapy.- Preliminary Results of Treatment with Intraconazole in Patients with Systemic Fungal Infections.- Lymphocyte Contamination in Leukocyte-Depleted Red Cell and Platelet Concentrates Obtained by Filtration.- Effects of Verapamil on Anthracycline-Induced Cardiomyopathy: Preliminary Results of a Prospective Multicenter Trial.- Prospective Study on the Influence of Disease or Treatment on Pituitary Function in 31 Children with Acute Leukemia and Non-Hodgkin’s Lymphoma.- Incidence of Aseptic Osteonecrosis Following the Therapy of Childhood Leukemia.- Osteoporosis in Children with Leukemia: A Potentially Debilitating Anomaly?.- Principles of Supportive Psychological Care for Patients Undergoing Bone Marrow Transplantation.- Fibronectin in Stomatitis Therapy of Leukemic Children.- Treatment of Relapse and Pharmacokinetics.- Karyotype of Leukemia Cells Consistently Predicts for Response to Therapy and Survival Following Salvage Therapy in Acute Myeloblastic Leukemia.- Proposal for the Classification of Relapsed and Refractory Acute Myeloid Leukemias as the Basis for an Age-Adjusted Randomized Comparison of Sequentially Applied High-Dose Versus Intermediate-Dose Cytosine Arabinoside in Combination with Mitoxantrone (S-HAM).- Pharmacologically Directed Design of Leukeumia Therapy.- Treatment of Relapsed or Refractory Acute Leukemia: Comparison of Two Different Regimens.- BFM Group Treatment Results in Relapsed Childhood Acute Lymphoblastic Leukemia.- Bone Marrow Transplantation.- Marrow Grafting for Acute Leukemia: Results and Future Treatment Strategies.- Bone Marrow Transplantation from Histocompatible Sibling Donors for Patients with Acute Lymphoblastic Leukemia.- Allogeneic Bone Marrow Transplantation in Childhood Leukemia: Results and Strategies in the Federal Republic of Germany.- Allogeneic and Autologous Bone Marrow Transplantation in Acute Leukemia: The Essen Experience.- Role of Cytokines and Major Histocompatibility Complex Antigens in Graft-Versus-Host Disease: In Vitro Studies Using T-Cell Lines and Keratinocytes or Hemopoietic Targets.- Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in First Remission: First Dutch Prospective Study.- Autologous Bone Marrow Transplantation for Acute Leukemia in Remission: An Analysis of 1322 Cases.- Role of Autologous Bone Marrow Transplantation in Acute Leukemia.- Long-Term Disease-Free Survival Following Autologous Bone Marrow/Blood Stem Cell Transplantation in 89 Patients with Acute Leukemia.- Allogeneic and Autologous Bone Marrow Transplantation for Acute Lymphoblastic Leukemia.- Treatment Strategies for Acute Lymphoblastic Leukemia.- Influence of Treatment Modality, Patient/Donor Characteristics, and Disease Stage on the Risk of Relapse After Allogeneic Marrow Transplantation for Acute Leukemia.- Comparison of Allogeneic and Autologous Bone Marrow Transplantation for Treatment of Acute Lymphocytic Leukemia in Childhood.- High-Dose Chemotherapy with Noncryopreserved Autologous Bone Marrow Transplantation for Acute Myeloblastic Leukemia in First Complete Remission.- Myelopoietic Reconstitution Following Autologous Bone Marrow Transplantation.- Bone Marrow Transplantation with a Fixed Low Number of T-Cells in the Graft.- Complotyping and Subtyping of MHC Class I Gene Products in Haplotype Determination for Bone Marrow Transplantation.- Complications of Bone Marrow Transplantation in Chinese.- Hematopoietic Growth Factors.- Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Neutropenia and Related Morbidity Induced by Myelotoxic Chemotherapy.- Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor After Chemotherapy for Acute Leukemias at Higher Age or After Relapse.- Treatment of Poor-Prognosis, Newly Diagnosed Acute Myelogenous Leukemia with High-Dose Cytosine Arabinoside (Ara-C) and rHUGM-CSF.- Use of Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor to Speed Engraftment and Treat Graft Failure Following Marrow Transplantation in Man.- Regeneration of Granulopoiesis with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor After Autologous Bone Marrow Transplantation.- Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside.- Effect of Treatment with rgGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes.